MIP2018

MIP NANOPARTICLES IN DIAGNOSTICS AND LIFE SCIENCE APPLICATIONS

Sergey Piletsky
Department of Chemistry, Leicester Biotechnology Group

Five years ago we have made a major breakthrough in MIP technology developing solid-phase approach for preparation of soluble molecularly imprinted nanoparticles (nanoMIPs) with exquisite affinity and selectivity for their templates. The success came from combining controlled radical polymerisation with an affinity separation step performed on surface-immobilised template. This approach represents the state-of-the-art in nanoMIP synthesis: not only are soluble particles with defined size (20-200 nm) and a narrow size distribution produced in one hour, they possess subnanomolar dissociation constants for their respective targets, they can be easily functionalised with fluorescent, electrochemical or magnetic labels, and the immobilised template can be re-used. High affinity nanoMIPs were made for small molecules, proteins, membrane proteins and virus particles.

The main practical niches for application of synthesised nanoMIPs are diagnostics, imaging and drug delivery. Members of our team have used nanoMIPs successfully as a replacement for antibodies in ELISA-type assays, electrochemical and optical sensors. The exciting examples of our work with in vivo application potential are targeting membrane receptors, enzymes and quorum sensing molecules. NanoMIPs were used in life science to identify peptide epitopes for antibodies and membrane proteins. Very encouraging facts that enables practical applications of MIPs in vivo are lack of polymer toxicity, ability of nanoMIPs to penetrate into cells and to pass blood barrier. Current paper discusses challenges and opportunities that are faced by MIP technology in the light of these developments.

References

  1. Poma A., Guerreiro A., Whitcombe M. J., Piletska E., Turner A. P. F., Piletsky S. (2013). Solid-phase synthesis of molecularly imprinted polymer nanoparticles with a reusable template (“plastic antibodies"). Adv. Functional. Mater., 23, 2821-2827.
  2. Guerreiro A., Poma A., Moczko E., Takarada J., Vargas-Sansalvador I. P., Turner N., Piletska E., Magalhães C. S., Glazova N., Serkova A., Omelianova A., Karim K., Piletsky S. (2014). Influence of surface-imprinted nanoparticles on trypsin activity. Adv. Healthcare Mat., 3, 1426-1429.
  3. Canfarotta F., Waters A., Sadler R., McGill P., Guerreiro A., Papkovsky D., Haupt K., Piletsky S. (2016). Biocompatibility and internalization of molecularly imprinted nanoparticles. Nano Research, 9, 3463–3477.
  4. Smolinska-Kempisty K., Guerreiro A., Canfarotta F., Caceres C., Whitcombe M., Piletsky S. (2016). A comparison of the performance of molecularly imprinted polymer nanoparticles for small molecule targets and antibodies in the ELISA format. Sci. Reports, 6, 37638.
  5. Cecchini A., Raffa V., Canfarotta F., Signore G., Piletsky S., MacDonald M., Cuschieri A. (2017). In vivo recognition of human vascular endothelial growth factor by molecularly imprinted polymers. NanoLetters, 17, 2307-2312.
Sergey Piletsky
Sergey Piletsky
Head of LBG
University of Leicester








Powered by Eventact EMS